393,827 Edwards Lifesciences Corporation $EW Shares Sold by Ninety One UK Ltd

Ninety One UK Ltd trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,943,675 shares of the medical research company’s stock after selling 393,827 shares during the quarter. Edwards Lifesciences makes up 2.4% of Ninety One UK Ltd’s portfolio, making the stock its 8th biggest position. Ninety One UK Ltd’s holdings in Edwards Lifesciences were worth $1,030,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in EW. BlackRock Inc. acquired a new stake in Edwards Lifesciences during the second quarter worth about $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences in the second quarter worth $1,274,082,000. Bank of America Corp DE acquired a new stake in Edwards Lifesciences in the second quarter worth $605,397,000. Deutsche Bank AG acquired a new stake in Edwards Lifesciences in the second quarter worth $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Edwards Lifesciences by 0.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock worth $496,503,000 after purchasing an additional 30,495 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on EW shares. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. UBS Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Thursday, October 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Up 0.1%

Shares of Edwards Lifesciences stock traded up $0.08 during midday trading on Thursday, hitting $86.53. The company’s stock had a trading volume of 1,294,080 shares, compared to its average volume of 4,491,407. Edwards Lifesciences Corporation has a 1-year low of $72.42 and a 1-year high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $49.82 billion, a P/E ratio of 49.80, a PEG ratio of 2.23 and a beta of 0.87. The stock has a 50-day simple moving average of $88.53 and a 200-day simple moving average of $86.27.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business earned $0.67 EPS. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.